I am posting this on behalf of my colleague. Please see details below.

We are seeking from colleagues cases of suspected canine epileptoid cramping syndrome in Border Terriers or of suspected Scottie cramp for the purpose of genetic research.  Identification of a DNA marker for these conditions may help us to identify the cause of these disorders, accurately diagnose them and advise breeders in their breeding programs. 

A syndrome known as canine epileptoid cramping syndrome (also known as Spike’s disease) has been observed in Border Terriers. Episodes consist of gait abnormalities ranging from ataxia to an inability to stand, contractions of abdominal, neck and back muscles resulting in abnormal posturing and contractions/cramping of the appendicular muscle (extensor rigidity or flexion of the limbs). Duration of the episodes can vary from seconds to half an hour or longer during which the dog remains aware of his surrounding.  Increased intestinal motility is suspected based on hearing borborygmus. Affected dogs may experience pain during the episodes. 

Scottie cramp is a syndrome observed in young adult Scottish Terriers consisting of involuntary sustained muscle contractions primarily affecting the hind limbs. With excitement, the hind limbs assume a hypertonic, extended position or they may occasionally display exaggerated flexion of the limbs. The forelimbs become abducted and develop increased extensor tone. Affected dogs progressively develop a stiff stilted gait over a few minutes. Severely affected dogs assume an arched posture over their back and may fall into lateral recumbency with their head and tail flexed.

If you have a case of suspected canine epileptoid cramping syndrome or of suspected Scottie cramp, please contact Dr Laurent Garosi at Davies Veterinary Specialists (lsg@vetspecialists.co.uk or telephone 01582 883950). 

Dr Laurent S Garosi DVM, MRCVS, Dip ECVN – Head of neurology/neurosurgery - Davies Veterinary Specialists, Higham Gobion, England

Prof Robert J Harvey BSc, PhD – Professor of Molecular Neuroscience and Genetics, Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London, England

Mark Lowrie